This seems likely, only because they did extend CD

This seems likely, only because they did extend CD12 and there is no announced protocol approval from the fda for any other different covid trials. What I am wondering is if the problem with the 2 dose limit is altered? Or, do they shorten the 28 days to 14? I guess extending cd12 until we get statistical power is quicker than starting a whole new trial. It could also explain the lack of an EUA, could be the FDA realizes how close the data is and wants to just move a little further to an approval instead of going in another direction.